EUVIMEDEUVIMED entdecken
Crossref

An Exploratory Application of a Central Nervous System (CNS) Tumor Methylation Classifier in Ovarian Neuroectodermal Tumors

Jie Yang, Tianyu Zhang, Ying Zhang, Xinyue Zhang, Yang Xiang, Huanwen Wu, Leiming Wang, Xiaohua Shi, Jiaxin Yang

Modern Pathology · 2026

DOI: 10.1016/j.modpat.2025.100930 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Modern Pathology, 2026. Verfasst von Jie Yang und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Obstetrics and Gynecology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College,…. Hauptthemen laut MEDLINE: DNA Methylation, Ovarian Neoplasms, Biomarkers, Tumor, Neuroectodermal Tumors. Die Arbeit nennt 45 Literaturangaben. Gefördert von: Peking Union Medical College Hospital, National Key Clinical Specialty Discipline Construction Program of China, National Key Research and Development Program of China.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Ovarian neuroectodermal tumors (NETs) are rare malignancies with unclear diagnostic criteria and challenging treatment. We aimed to assess the utility of DNA methylation in the diagnostic classification and prognostic stratification of ovarian NETs. This retrospective study included 15 patients diagnosed with ovarian NETs at Peking Union Medical College Hospital between 2010 and 2024. Paraffin-embedded tumor tissues from all patients underwent clinicopathologic review, DNA methylation microarray assay, EWSR1 fluorescence in situ hybridization, and immunohistochemistry. The median age at diagnosis of ovarian NETs was 19 years (range, 9-73 years). These tumors often displayed nonspecific clinical manifestations and were frequently diagnosed at an advanced stage. Morphologic diagnosis included 3 medulloblastoma, 1 neuroblastoma, 3 embryonal tumors with multilayered rosettes (ETMRs), 3 ependymomas, 1 high-grade glioma, 1 gliosarcoma, 1 low-grade neuronal-glial tumor, and 2 tumors that cannot be specified. A teratoma background was present in 73.3% (11/15) of the cases. None of the tumors exhibited EWSR1 gene rearrangement. Methylation classification was consistent with morphologic diagnosis in 30% of patients (5/15). A novel ETMR, non-C19MC-altered type ovarian tumor was identified in 3 patients. The median follow-up period of all patients was 14.9 months (range, 2.1-216.4 months), during which 60.0% of patients experienced recurrence or disease progression, and the mortality rate was 33.3%. Patients with ETMR non-C19MC-altered subtype and unmatched tumors exhibited extremely poor outcomes, with 80% (4/5) mortality within 12 months. DNA methylation profiling classified a subset of ovarian NETs into molecular subtypes resembling those of central nervous system (CNS) tumor counterparts, with corresponding prognostic similarities. Leveraging the CNS tumor methylation classifier to diagnose peripheral neuroectodermal tumors may offer critical clinical insights for these rare malignancies, enabling molecular subtyping, prognostication, and alignment with CNS-targeted therapeutic strategies.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

DNA MethylationOvarian NeoplasmsBiomarkers, TumorNeuroectodermal TumorsHumansFemaleAdultChildYoung AdultAdolescentMiddle AgedAgedRetrospective StudiesPrognosis

Stichwörter der Autor:innen

DNA methylationdiagnosismolecular classificationovarian neuroectodermal tumorsprognosis

Substanzen

Biomarkers, Tumor

Autor:innen und Institutionen

  • Department of Obstetrics and Gynecology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, National Clinical Research Center for Obstetric & Gynecologic Disease…
  • Department of Pathology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
  • Department of Pathology, Xuanwu Hospital, Capital Medical University, Beijing, China. Electronic address: Wangleiming0918@163.com.
  • Department of Pathology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China. Electronic address: shixiaohua3762@foxmail.com.

Förderung

  • Peking Union Medical College Hospital
  • National Key Clinical Specialty Discipline Construction Program of China
  • National Key Research and Development Program of China

Zitieren

APA

Yang, J., Zhang, T., Zhang, Y., Zhang, X., Xiang, Y., Wu, H., Wang, L., Shi, X., & Yang, J. (2026). An Exploratory Application of a Central Nervous System (CNS) Tumor Methylation Classifier in Ovarian Neuroectodermal Tumors. Modern Pathology. https://doi.org/10.1016/j.modpat.2025.100930

Vancouver

Yang J, Zhang T, Zhang Y, Zhang X, Xiang Y, Wu H, et al. An Exploratory Application of a Central Nervous System (CNS) Tumor Methylation Classifier in Ovarian Neuroectodermal Tumors. Modern Pathology. 2026. doi:10.1016/j.modpat.2025.100930

BibTeX
@article{Yang2026,
  author = {Yang, Jie and Zhang, Tianyu and Zhang, Ying and Zhang, Xinyue and Xiang, Yang and Wu, Huanwen and Wang, Leiming and Shi, Xiaohua and Yang, Jiaxin},
  title = {An Exploratory Application of a Central Nervous System (CNS) Tumor Methylation Classifier in Ovarian Neuroectodermal Tumors},
  journal = {Modern Pathology},
  year = {2026},
  doi = {10.1016/j.modpat.2025.100930}
}
Kostenlos starten →